ReviewMolecular therapy : the journal of the American Society of Gene Therapy2016
Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.
Review in Molecular therapy : the journal of the American Society of Gene Therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 39 citations in OpenAlex.
- Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases.Gene therapy · 2025Review
- Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B.Current hepatology reports · 2024Article
- Host cell-dependent late entry step as determinant of hepatitis B virus infection.PLoS pathogens · 2022Article
- Chronic hepatitis B: New potential therapeutic drugs target.World journal of virology · 2022Review
- Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review.International journal of molecular sciences · 2021Review
- Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B.Microorganisms · 2021Review
- Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate HeterodimericViruses · 2021Article
- Review
- Recent Advances in Hepatitis B Treatment.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Optimization of AAV vectors to target persistent viral reservoirs.Virology journal · 2021Review
- Review
- Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing.Molecular therapy. Nucleic acids · 2020Article
- Hepatitis B: Current Status of Therapy and Future Therapies.Gastroenterology clinics of North America · 2020Review
- CRISPR-Cas13a Cleavage of Dengue Virus NS3 Gene Efficiently Inhibits Viral Replication.Molecular therapy. Nucleic acids · 2020Article
- Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA.BMC infectious diseases · 2019Article
- CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge.Molecules (Basel, Switzerland) · 2019Review
- [Status and progress in chronic hepatitis B cure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018Article
- Disease Pathways and Mechanisms of Potential Drug Targets.Clinical liver disease · 2018Review
- CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile?ACS infectious diseases · 2018Review
- The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.ACS chemical biology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic infection with hepatitis B virus (HBV) occurs in approximately 6% of the world's population. Carriers of the virus are at risk for life-threatening complications, and developing curative treatment remains a priority. The main shortcoming of licensed therapies is that they do not affect viral covalently closed circular DNA (cccDNA), a stable intermediate of replication. Harnessing gene editing to mutate cccDNA provides the means to inactivate HBV gene expression permanently. Reports have described use of engineered zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR) with CRISPR-associated (Cas) nucleases. Although inhibition of viral replication has been demonstrated, reliably detecting mutations in cccDNA has been difficult. Also, the dearth of murine models that mimic cccDNA formation has hampered analysis in vivo. To reach a stage of clinical use, efficient delivery of the editors to HBV-infected hepatocytes and limiting unintended off-target effects will be important. Investigating therapeutic efficacy in combination with other treatment strategies, such as immunotherapies, may be useful to augment antiviral effects. Advancing gene editing as a mode of treating HBV infection is now at an interesting stage and significant progress is likely to be made in the immediate future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.